Synapse - Dean Bajorin

Results (663)

A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC)

Meeting Abstract

Funt, S. A.; Jatwani, K.; Makris, M.; Regazzi, A. M.; Lee, C. H.; Teo, M. Y.; McHugh, D. J.; McCoy, A. S.; Hettich, G.; Wong, P.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT)

Meeting Abstract

Feldman, D. R.; Hu, J. S.; Patil, S.; Reuter, V. E.; Srinivas, S.; Stadler, W. M.; Costello, B. A.; Milowsky, M. I.; Appleman, L. J.; Dorff, T. B.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results

Meeting Abstract

Dizman, N.; Rosenberg, J. E.; Hoffman-Censits, J. H.; Quinn, D. I.; Petrylak, D. P.; Galsky, M. D.; Vaishampayan, U. N.; De Giorgi, U.; Gupta, S.; Burris, H. A.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG): Updated follow-up from KEYNOTE-057

Meeting Abstract

De Wit, R.; Kulkarni, G. S.; Uchio, E. M.; Krieger, L. E. M.; Boormans, J. L.; Roumiguié, M.; Singer, E. A.; Bajorin, D. F.; Kamat, A. M.; Grivas, P.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Clinical features and outcomes of secondary somatic malignancy (SSM) arising from teratoma in late relapse germ cell tumor (GCT)

Meeting Abstract

Wong, N. C.; Dason, S.; Dean, L. W.; Isharwal, S.; Donoghue, M.; Jia, L.; Joseph, G.; Tap, W. D.; Funt, S. A.; McHugh, D. J.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors

Meeting Abstract

Sonpavde, G.; Hennessy, D.; Manitz, J.; Niegisch, G.; Powles, T.; Rosenberg, J. E.; Bajorin, D. F.; Apolo, A. B.; Pond, G. R.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Invasive urothelial cancer (iUC) with FGFR3 hotspot mutation/fusion (FGFR3+): A molecularly and clinically distinctive entity?

Meeting Abstract

Mota, J. M. S. C.; Teo, M. Y.; Li, H.; Balar, A. V.; Milowsky, M. I.; Funt, S. A.; Lee, C. H.; Regazzi, A. M.; Berger, M. F.; Solit, D. B.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Defining "platinum-ineligible" patients with metastatic urothelial cancer (mUC)

Meeting Abstract

Gupta, S.; Sonpavde, G.; Grivas, P.; Apolo, A. B.; Plimack, E. R.; Flaig, T. W.; Hahn, N. M.; Balar, A. V.; Bajorin, D. F.; Galsky, M. D.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Durable clinical benefit from combination ipilimumab (IPI) and nivolumab (NIVO) in anti-PD-1 therapy resistant, platinum resistant metastatic urothelial carcinoma (mUC)

Meeting Abstract

Keegan, N. M.; Funt, S. A.; Kania, B. E.; Iyer, G.; Clement, J. M.; McCoy, A. S.; Hettich, G.; Ziv, E.; Maher, C. A.; Nair, S.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Clinical features and outcomes of secondary somatic malignancy (SSM) associated with primary mediastinal nonseminomatous germ cell tumors (PM-NSGCT)

Meeting Abstract

Dean, L. W.; Wong, N. C.; Dason, S.; Isharwal, S.; Donoghue, M.; Jia, L.; Tap, W. D.; Joseph, G.; Funt, S. A.; McHugh, D. J.; more...
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save